<DOC>
	<DOCNO>NCT01263587</DOCNO>
	<brief_summary>The primary purpose study describe participant hepatitis B virus ( HBV ) infection identify factor may cause disease activate worsen .</brief_summary>
	<brief_title>Hepatitis B Research Network Adult Cohort Study</brief_title>
	<detailed_description>Aims - Primary Aim : To describe participant hepatitis B virus ( HBV ) infection prospective cohort United States ( US ) Canada identify predictor disease activation progression - Secondary Aims : - To describe clinical , virological , immunological characteristic participant HBV US Canada - To evaluate change HBV infection status quantitative hepatitis B surface antigen ( HBsAg ) level factor associate change - To verify whether baseline HBsAg 1,000 IU/mL HBV DNA 1,000 IU/mL accurate predictor people , become , inactive carrier , define people HBsAg positive , hepatitis B `` e '' antigen ( HBeAg ) negative , normal Alanine transaminase ( ALT ) HBV DNA 1,000 IU/mL least two occasion period least 6 month - To develop bank biospecimens ( e.g. , serum , plasma , DNA , lymphocytes , liver tissue ) obtain participant HBV infection - To identify participant HBV infection potential candidate one treatment study conduct Hepatitis B Research Network ( HBRN ) - To describe natural history hepatitis B infection pregnancy include frequency , clinical virological characteristic associate , hepatic flare pregnancy post-partum .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<criteria>The study population recruit multisite clinical center United States Canada include primary care hospital community center . Inclusion criterion Written inform consent At least 18 year age Hepatitis B surface antigen ( HBsAg ) positive either : Pregnant AntiHepatitis D positive Diagnosed acute Hepatitis B infection experience hepatitis flare Immune tolerant immune active phenotype Potentially eligible Immune Regulation Costimulation Natural History Chronic Hepatitis B ancillary study ( NCT01298037 ) . Hepatic decompensation Hepatocellular carcinoma ( HCC ) Liver transplantation Current hepatitis B antiviral treatment ( except pregnant woman patient antiHDV positive ) Known Human immunodeficiency virus ( HIV ) coinfection ( patient Hepatitis D ( HDV ) Hepatitis C ( HCV ) coinfection exclude ) . Medical social condition opinion investigator interfere prevent followup per protocol Unable unwilling return followup visit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Hepatitis B</keyword>
	<keyword>HBV</keyword>
	<keyword>Cohort Study</keyword>
</DOC>